• Blog
  • Acute Lung Injury Market Growth Analysis | 2023-2028

    Acute Lung Injury Market Growth Analysis | 2023-2028

    Acute Lung Injury Market Growth Analysis | 2023-2028
    Report code - SR1746 Delivery - 2 Weeks
    Acute Lung Injury Market Size, Share, Trends, Forecast, & Growth Analysis - 2023-2028
    See more...

    Market Insights

    The acute lung injury market was estimated at USD 3.05 billion in 2022 and is likely to grow at a CAGR of 3.24% during 2023-2028 to reach USD 3.69 billion in 2028.

    Acute-Lung-Injury-Market-Insights

    Want to know more about the market scope? Register Here

    What is acute lung injury?

    Acute lung injury (ALI) is referred to as a severe condition which is caused by acute hypoxemic respiratory failure. It is a vital source of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema. The symptoms seen in acute lung injury patients are severe shortness of breath, low blood pressure, confusion, and extreme tiredness. ALI is primarily diagnosed clinically based on the presence of non-cardiogenic pulmonary edema and respiratory failure in a critically ill patient.

    Covid-19 Impact

    The outbreak of COVID-19 moderately affected the acute lung injury industry. Due to the diversion of the medical field in treating COVID-19 patients, the funding for R&D activities related to lung injuries has been reduced, they have faced negligence which has hurt the market growth. Patients with acute lung injury are highly prone to COVID-19 and thus have some access to appointments and treatments.

    Acute Lung Injury Market Report Highlights

    Market Size in 2022

    USD 3.05 billion

    Market Size in 2028

    USD 3.69 billion

    Market Growth (2023-2028)

    3.24% CAGR

    Base Year of Study

    2022

    Trend Period

    2017-2021

    Forecast Period

    2023-2028

    Key Players

    Key players operating in the global market are-

    • GlaxoSmithKline plc (UK)
    • INO Therapeutics, LLC (US)
    • Octapharma AG (Switzerland)
    • Ono Pharmaceutical Co., Ltd. (Japan)
    • Eli Lilly and Company (US)
    • Chiesi S. p. A. (Italy)
    • B. Braun Melsungen AG (Germany)
    • Altor BioScience Corporation (US)
    • Apeptico (Austria)
    • Forschung und Entwicklung GmbH (Austria)  

    Market Dynamics

    The acute lung injury market is mainly driven by the increasing geriatric population and technological developments. Many countries across the globe are facing challenges mainly due to the ongoing and rising demographic shift in age among the people. Moreover, with surging awareness related to daily health diagnostics, patients are likely to prefer digital diagnostics over laboratory or hospital visits, and this technology platform further augments the market growth.

    Acute-Lung-Injury-Market-Dynamics

    Want to have a closer look at this market report? Click Here

    Segments Analysis

    By Therapy Type

    Based on therapy, the acute lung injury market has been classified into mechanical ventilation, pharmacotherapy, and fluid management. The mechanical ventilation segment accounted for the largest market share in 2022, owing to its primary choice for the supportive treatment of patients suffering from acute lung injury (ALI). It includes the delivery of air/oxygen at tidal volumes and frequencies to be enough to reduce the pressure on breathing with simultaneous progress in oxygenation, which further augments the segment growth.

    Regional Insights

    By region, North America accounted for a significant share in 2022 and is expected to grow at a robust CAGR during the review period. The Acute Lung Injury market growth is mainly propelled by the rising prevalence of acute lung injuries in the region. As per the Lung Disease Research Funding, around 75,000 people in the U.S. die because of acute lung injury every year, thus boosting the market growth in the region.

    The Asia Pacific is expected to grow at a healthy CAGR during the review on account of growing awareness associated with lung injury treatment, the presence of a large population base, and increasing healthcare expenditure. Moreover, the rising incidence of pulmonary infections in the region that require the use of medications and devices for the treatment of lung injury further bolsters the regional market growth.

    Acute-Lung-Injury-Market-Regional-Insights

    Know the high-growth countries in this report. Click Here

    Critical Questions Answered in the Report

    • What are the key trends in the global market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the global market?
    • What are the key strategies adopted by the major vendors to lead in the global market?
    • What is the market share of the top vendors?

    Market Segmentation

    This report studies the market covering 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

    The acute lung injury market is segmented into the following categories:

    By Therapy Type

    • Mechanical Ventilation
    • Pharmacotherapy
    • Fluid Management

    By End-Use Type

    • Hospitals
    • Clinics
    • Others

    By Region

    • North America (Country Analysis: The USA, Canada, and Mexico)
    • Europe (Country Analysis: Germany, France, The UK, Russia, and The Rest of Europe)
    • Asia-Pacific (Country Analysis: Japan, China, India, and The Rest of Asia-Pacific)
    • Rest of the World (Country Analysis: Brazil, Argentina, and Others)

    Acute-Lung-Injury-Market-Segmentation

    Click Here, to learn the market segmentation details.

    Target Audience

    The target audience of the acute lung injury market includes-

    • Acute Lung Injury Vendors
    • Acute Lung Injury Manufacturers
    • Acute Lung Injury Distributors
    • Organizations
    • Government Bodies.

    Research Methodology

    This strategic assessment report, from Stratview Research, provides a comprehensive analysis that reflects today’s acute lung injury market realities and future market possibilities for the forecast period. The report segments and analyzes the market in the most detailed manner in order to provide a panoramic view of the market.

    The vital data/information provided in the report can play a crucial role for market participants as well as investors in the identification of the low-hanging fruits available in the market as well as to formulate growth strategies to expedite their growth process.

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

    More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data.

    We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into market dynamics and will enable strategic decision-making for existing market players as well as those willing to enter the market.

    What Deliverables Will You Get in this Report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth Analysis of the Acute Lung Injury Market

    How lucrative is the future?

    Market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional, and country-level historical data and forecasts

    Which are the most attractive market segments?

    Market Segment Analysis and Forecast

    Which are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirements?

    10% free customization

    Report Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

    Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    Acute lung injury (ALI) is referred to as a severe condition which is caused by acute hypoxemic respiratory failure. It is a vital source of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema. The symptoms seen in acute lung injury patients are severe shortness of breath, low blood pressure, confusion, and extreme tiredness. ALI is primarily diagnosed clinically based on the presence of non-cardiogenic pulmonary edema and respiratory failure in a critically ill patient.

    The acute lung injury market was estimated at USD 3.05 billion in 2022.

    The acute lung injury market is likely to reach USD 3.69 billion in 2028.

    The acute lung injury market is estimated to grow at a healthy CAGR of 3.24% during the forecast period.

    Key players operating in the global market are- GlaxoSmithKline plc (UK), INO Therapeutics, LLC (US), Octapharma AG (Switzerland), Ono Pharmaceutical Co., Ltd. (Japan), Eli Lilly and Company (US), Chiesi S. p. A. (Italy), B. Braun Melsungen AG (Germany), Altor BioScience Corporation (US), Apeptico (Austria), Forschung und Entwicklung GmbH (Austria).

    The market is mainly driven by increasing geriatric population and technological developments.

    North America accounted for a significant share in 2022 and is expected to grow at a robust CAGR during the review period.

    The target audience of the market includes- Acute Lung Injury Vendors, Acute Lung Injury Manufacturers, Acute Lung Injury Distributors, Organizations, Government Bodies.